CL2021000440A1 - El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión. - Google Patents

El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión.

Info

Publication number
CL2021000440A1
CL2021000440A1 CL2021000440A CL2021000440A CL2021000440A1 CL 2021000440 A1 CL2021000440 A1 CL 2021000440A1 CL 2021000440 A CL2021000440 A CL 2021000440A CL 2021000440 A CL2021000440 A CL 2021000440A CL 2021000440 A1 CL2021000440 A1 CL 2021000440A1
Authority
CL
Chile
Prior art keywords
alpha
adrenergic receptor
improve vision
receptor agonists
visual
Prior art date
Application number
CL2021000440A
Other languages
English (en)
Spanish (es)
Inventor
Mohammed Dibas
Daniel W Gil
Wayne Chen
Miguel Alcantara
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2021000440A1 publication Critical patent/CL2021000440A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021000440A 2018-08-21 2021-02-22 El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión. CL2021000440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862720671P 2018-08-21 2018-08-21

Publications (1)

Publication Number Publication Date
CL2021000440A1 true CL2021000440A1 (es) 2021-09-20

Family

ID=67841225

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000440A CL2021000440A1 (es) 2018-08-21 2021-02-22 El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión.

Country Status (17)

Country Link
US (4) US20210205273A1 (https=)
EP (1) EP3840750A1 (https=)
JP (1) JP2021534217A (https=)
KR (1) KR20210047323A (https=)
CN (1) CN112823003A (https=)
AR (1) AR115991A1 (https=)
AU (1) AU2019325486A1 (https=)
BR (1) BR112021003295A2 (https=)
CA (1) CA3110318A1 (https=)
CL (1) CL2021000440A1 (https=)
CO (1) CO2021003460A2 (https=)
IL (1) IL280990A (https=)
MX (1) MX2021002112A (https=)
PH (1) PH12021550372A1 (https=)
SG (1) SG11202101730SA (https=)
TW (1) TW202021584A (https=)
WO (1) WO2020041340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514732A (ja) * 2020-02-20 2023-04-07 アラーガン、インコーポレイテッド アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP3085358B1 (en) 2010-01-22 2017-11-01 Allergan, Inc. Intracameral sustained release therapeutic agent implants
WO2012149381A1 (en) * 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
JP2016515583A (ja) 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
CN103338483B (zh) * 2013-07-24 2016-08-10 成都西加云杉科技有限公司 数据分流方法、数据分流设备及异构网络
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11077053B2 (en) * 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Also Published As

Publication number Publication date
WO2020041340A1 (en) 2020-02-27
JP2021534217A (ja) 2021-12-09
BR112021003295A2 (pt) 2021-05-18
AU2019325486A1 (en) 2021-03-25
KR20210047323A (ko) 2021-04-29
CO2021003460A2 (es) 2021-04-08
AR115991A1 (es) 2021-03-17
EP3840750A1 (en) 2021-06-30
MX2021002112A (es) 2021-07-16
US20220288031A1 (en) 2022-09-15
SG11202101730SA (en) 2021-03-30
PH12021550372A1 (en) 2021-11-29
IL280990A (en) 2021-04-29
US20240358682A1 (en) 2024-10-31
US20210205273A1 (en) 2021-07-08
CN112823003A (zh) 2021-05-18
CA3110318A1 (en) 2020-02-27
TW202021584A (zh) 2020-06-16
US20220160623A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2021000440A1 (es) El uso de agonistas del receptor alfa-2-adrenérgico para mejorar la visión.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
ECSP20013332A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX358176B (es) El uso de intensificadores, posiblemente asociados con riboflavina, asi como composiciones oftalmicas correspondientes para reticulacion de la cornea, en el tratamiento de queratocono o de otras alteraciones ectasicas de la córnea.
MX2018014869A (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
CL2020002774A1 (es) Tratamiento combinado de fibrosis y/o angiogénesis ocular
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
UY35258A (es) ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS
CL2017002913A1 (es) Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
EA201791005A1 (ru) Улучшенные антитела против il-6
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2022015854A (es) Sistemas y metodos para mitigar la interferencia dentro del espectro usado activamente.
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.
CU20210008A7 (es) Aspirasas solubilizadas
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
ECSP15009391A (es) siARN Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES DE LOS OJOS